Description: Cardiff Oncology, Inc., a clinical-stage, oncology therapeutic company, develops drugs to treat various types of cancer, including leukemia, lymphomas, and solid tumors. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for metastatic Colorectal Cancer in combination with FOLFIRI and Avastin. The company's onvansertib is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer; Phase I clinical trial with various chemotherapies and targeted therapeutics, such as Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) used in leukemias, lymphomas, and solid tumor cancers. It primarily serves pharmaceutical companies. Cardiff Oncology, Inc. has a research collaboration with Nektar Therapeutics for the treatment of metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2020. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.
Home Page: www.cardiffoncology.com
CRDF Technical Analysis
11055 Flintkote Avenue
San Diego,
CA
92121
United States
Phone:
858 952 7570
Officers
| Name | Title |
|---|---|
| Dr. Mark Erlander Ph.D. | CEO & Director |
| Mr. James E. Levine | Chief Financial Officer |
| Ms. Vicki Kelemen | Chief Operating Officer |
| Dr. Tod Smeal Ph.D. | Chief Scientific Officer? |
| Ms. Elizabeth Anderson | VP of Fin. & Admin. |
| Mr. Charles Monahan R.Ph. | Sr. VP of Regulatory Affairs |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5643 |
| Price-to-Sales TTM: | 159.9695 |
| IPO Date: | 2004-07-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 22 |